Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Carnitine palmitoyltransferase 1A | Starlite/ChEMBL | No references |
Rattus norvegicus | Carnitine palmitoyltransferase 2 | Starlite/ChEMBL | No references |
Homo sapiens | carnitine palmitoyltransferase 2 | Starlite/ChEMBL | No references |
Homo sapiens | carnitine palmitoyltransferase 1A (liver) | Starlite/ChEMBL | No references |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.0771 uM | SUPPLEMENTARY: Inhibition of Carnitine palmitoyltransferase 1, liver isoform | ChEMBL. | No reference |
IC50 (binding) | = 0.1562 uM | SUPPLEMENTARY | SUPPLEMENTARY. | No reference |
IC50 (binding) | = 2.3168 uM | SUPPLEMENTARY | SUPPLEMENTARY. | No reference |
IC50 (binding) | = 5.2306 uM | SUPPLEMENTARY: Inhibition of Carnitine palmitoyltransferase 2 | ChEMBL. | No reference |
IC50 (binding) | > 100 uM | SUPPLEMENTARY: Inhibition of Carnitine palmitoyltransferase 1, muscle isoform | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.